United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - prochlorperazine edisylate (unii: pg20w5vqzs) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg in 1 ml - to control severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. do not use in patients with known hypersensitivity to phenothiazines. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in pediatric patients under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - trifluoperazine hydrochloride (unii: 6p1y2snf5v) (trifluoperazine - unii:214izi85k3) - trifluoperazine 1 mg - for the management of schizophrenia. trifluoperazine hydrochloride tablets, usp are effective for the short-term treatment of generalized non-psychotic anxiety. however, trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). when used in the treatment of non-psychotic anxiety, trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of trifluoperazine hydrochloride tablets as a treatment for non-psychotic anxiety was established in a 4-week clinical multicenter study of outpatients with generalized anxiety disorder (dsm-iii). this evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). trifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation. a known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and preexisting liver damage.

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - prochlorperazine edisylate (unii: pg20w5vqzs) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine edisylate 5 mg in 1 ml - to control severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. do not use in patients with known hypersensitivity to phenothiazines. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in pediatric patients under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - prochlorperazine maleate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maize starch; purified water; colloidal anhydrous silica; magnesium stearate - nausea and vomiting due to various causes including migraine; vertigo due to meniere's syndrome, labyrinthitis and other causes.

United States - English - NLM (National Library of Medicine)

direct_rx - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 25 mg - prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting. prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of out

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine suppositories, usp 25 mg are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting. prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine suppositories, usp 25 mg are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.